Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.rehab.2025.101933 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The effect of methylphenidate and amantadine co-administration on functional outcome of patients with blunt traumatic brain injury: A randomized controlled trial.
Acta Neurol Belg
July 2025
Trauma and Surgery Research Center, AJA University of Medical Sciences, Tehran, Iran.
Introduction: Traumatic brain injury (TBI) poses a large burden and cost on the patients, being among the most prevalent causes for emergency department visits. One of the major issues with TBI is the long-term functional outcome of patients, causing disabilities affecting the patient and the surrounding members of society. Several attempts have been made in order to address functional outcomes via means such as pharmacotherapy, physical therapy, and newer methods.
View Article and Find Full Text PDFCo-administration of methylphenidate and prism adaptation would require striatal integrity to alleviate spatial neglect: A preliminary study.
Ann Phys Rehabil Med
April 2025
Hôpital Henry Gabrielle, Hospices Civils de Lyon, 69230, France; Université Claude Bernard Lyon 1, CNRS, INSERM, Centre de Recherche en Neurosciences de Lyon CRNL U1028 UMR5229, TRAJECTOIRE team, Bron F-69500, France.
Effort-related motivational effects of methylphenidate: Reversal of the low-effort bias induced by tetrabenazine and enhancement of progressive ratio responding in male and female rats.
Neuropharmacology
May 2025
Department of Psychological Sciences, University of Connecticut, Storrs, CT, 06261-1020, USA. Electronic address:
Dopamine (DA) regulates behavioral activation and effort-related aspects of motivation. Blockade of DA storage by tetrabenazine (TBZ) induces depressive symptoms in humans, including fatigue and apathy. TBZ shifts choice behavior in rodents from high-effort to low-effort options, which can be used to model motivational symptoms observed in psychiatric disorders.
View Article and Find Full Text PDFThe Influence of Cannabidiol on the Pharmacokinetics of Methylphenidate in Healthy Subjects.
Med Cannabis Cannabinoids
November 2022
Department of Pharmacotherapy and Translational Research, University of Florida, Gainesville, Florida, USA.
Introduction: Cannabidiol (CBD) is a widely utilized nonpsychoactive cannabinoid available as an over-the-counter supplement, a component of medical cannabis, and a prescriptive treatment of childhood epilepsies. In vitro studies suggest CBD may inhibit a number of drug-metabolizing enzymes, including carboxylesterase 1 (CES1). The aim of this study was to evaluate effect of CBD on the disposition of the CES1 substrate methylphenidate (MPH).
View Article and Find Full Text PDFCombined Chronic Oral Methylphenidate and Fluoxetine Treatment During Adolescence: Effects on Behavior.
Curr Pharm Biotechnol
June 2023
Stanson Toshok Center for Brain Function and Repair, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USA.
Background: Attention Deficit Hyperactivity Disorder (ADHD) can be comorbid with depression, often leading to the prescription of both methylphenidate (MP) and selective serotonin reuptake inhibitor (SSRI) antidepressants, such as fluoxetine (FLX). Moreover, these drugs are often misused as cognitive enhancers. This study examined the effects of chronic oral co-administration of MP and FLX on depressive- and anxiety-like behaviors.
View Article and Find Full Text PDF